Suchergebnisse - "Maroto, Pablo"

PubPharm (116)

1

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Motzer, R. | Porta, C. | Eto, M. | +134

2

A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer : Results from CYCLONE 1

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Agarwal, N. | Castellano, D. | Alonso-Gordoa, T. | +16

3

Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy : a Spanish single-centre retrospective analysis

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024

von Tapia, J. | Gavira, J. | Anguera, G. | +8

4

Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma : A Single-Center Retrospective Study From 2004 to 2021

enthalten in: Clinical genitourinary cancer | 2024

von Tapia, J. | Bosma, F. | Gavira, J. | +6

5

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023

von Climent, M. | Álvarez, C. | Morales, R. | +15

6

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Grimm, M. | Esteban, E. | Barthélémy, P. | +40

7

Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma : Consensus of the uropathology group of the SEAP

enthalten in: Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia | 2023

von López-Beltrán, A. | González-Peramato, P. | Sanz-Ortega, J. | +6

8

Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition

enthalten in: International journal of cancer | 2023

von Roldán-Romero, J. | Valdivia, C. | Santos, M. | +14

9

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma : Analysis of the Phase 3 Randomized CLEAR Study

enthalten in: European urology oncology | 2023

von Grünwald, V. | Powles, T. | Kopyltsov, E. | +17

10

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment

enthalten in: Diagnostics (Basel, Switzerland) | 2023

von Cantó, E. | Anguera, G. | Jiménez, N. | +5

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]